COVID-19 Secondary Acute Lung Injury: FDA approves RLS-0071 for clinical trials.

!---- The U.S. FDA has accepted its application for a new research drug (IND) for RLS-0071 for the treatment of acute lung injury in THE secondary cause of COVID-19, pharmaceutical company ReAlta announced today.RLS-0071 is an engineered peptide with a dual-targeted mechanism designed to regulate its activation by interacting directly with immune cells while reducing excessive inflammation to suppress the complement and anti-inflammatory immune response.RLS-0071 was originally developed for the treatment of COVID-19-related acute lung injury and hypoxia ischemic encephalopathy (HIE).in patients with COVID-19, viral infections can lead to uncontrolled inflammation and acute lung damage.in preclinical disease models, RLS-0071 has the ability to regulate complement, neutrophil sylocutonias, and cytokines activation and reduce key inflammatory pathways leading to acute lung injury. Dr Ulrich Thienel, chief executive ofReAlta, said: "THE IMPACT OF COVID-19 ON PATIENTS CAN BE EXTREME, INCLUDING LIFE-THREATENING LUNG DISEASE.RLS-0071 may solve problems such as acute lung injury in THE secondary of COVID-19".acute lung injury is a combination of direct and indirect injury factors caused by alveolar epithelial cells and capillary endothelial cell damage, resulting in diffuse pulmonary interstitial and alveolar edema, resulting in acute hypoxia respiratory dysfunction..